TY - JOUR
T1 - Cannabinol delays symptom onset in SOD1 (G93A) transgenic mice without affecting survival
AU - Weydt, Patrick
AU - Hong, Soyon
AU - Witting, Anke
AU - Möller, Thomas
AU - Stella, Nephi
AU - Kliot, Michel
N1 - Funding Information:
This work was supported by a Leopoldina Fellowship (to PW), Mary Gates Scholarship (to SH), University of Washington Royalty Research Fund (to TM), Project ALS (to MK) and Valerie Estess (to PW and MK). We thank Drs. A. La Spada and G. Carter for comprehensive discussion.
PY - 2005/9
Y1 - 2005/9
N2 - Therapeutic options for amyotrophic lateral sclerosis (ALS), the most common adult-onset motor neuron disorder, remain limited. Emerging evidence from clinical studies and transgenic mouse models of ALS suggests that cannabinoids, the bioactive ingredients of marijuana (Cannabis sativa) might have some therapeutic benefit in this disease. However, Δ9-tetrahydrocannabinol (Δ9-THC), the predominant cannabinoid in marijuana, induces mind-altering effects and is partially addictive, compromising its clinical usefulness. We therefore tested whether cannabinol (CBN), a non-psychotropic cannabinoid, influences disease progression and survival in the SOD1 (G93A) mouse model of ALS. CBN was delivered via subcutaneously implanted osmotic mini-pumps (5 mg/kg/day) over a period of up to 12 weeks. We found that this treatment significantly delays disease onset by more than two weeks while survival was not affected. Further research is necessary to determine whether non-psychotropic cannabinoids might be useful in ameliorating symptoms in ALS.
AB - Therapeutic options for amyotrophic lateral sclerosis (ALS), the most common adult-onset motor neuron disorder, remain limited. Emerging evidence from clinical studies and transgenic mouse models of ALS suggests that cannabinoids, the bioactive ingredients of marijuana (Cannabis sativa) might have some therapeutic benefit in this disease. However, Δ9-tetrahydrocannabinol (Δ9-THC), the predominant cannabinoid in marijuana, induces mind-altering effects and is partially addictive, compromising its clinical usefulness. We therefore tested whether cannabinol (CBN), a non-psychotropic cannabinoid, influences disease progression and survival in the SOD1 (G93A) mouse model of ALS. CBN was delivered via subcutaneously implanted osmotic mini-pumps (5 mg/kg/day) over a period of up to 12 weeks. We found that this treatment significantly delays disease onset by more than two weeks while survival was not affected. Further research is necessary to determine whether non-psychotropic cannabinoids might be useful in ameliorating symptoms in ALS.
KW - Cannabinoids
KW - Motor neuron disease
KW - Mouse model
KW - Therapy
UR - http://www.scopus.com/inward/record.url?scp=26444608731&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=26444608731&partnerID=8YFLogxK
U2 - 10.1080/14660820510030149
DO - 10.1080/14660820510030149
M3 - Article
C2 - 16183560
AN - SCOPUS:26444608731
SN - 2167-8421
VL - 6
SP - 182
EP - 184
JO - Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders
JF - Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders
IS - 3
ER -